Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU

Inclusion Criteria

• •1. The subjects voluntarily joined this study and signed the informed consent form.
• •2. Age: 18 to 75 years old, gender not limited;
• •3. ECOG PS score: 0-2 points
• •4. Patients with unresectable or metastatic colorectal cancer confirmed by histology or cytology, where the primary tumor location and the status of RAS and BRAF are known;
• •5. No previous treatment for unresectable or metastatic lesions has been received;
• •6. There is at least one measurable lesion in accordance with the RECIST 1.1 standard;
• •7. In the pre-treatment examination indicators, there was no serious hematopoietic function abnormality, and the functions of the heart, lungs, liver and kidneys were basically normal.
• •1. Hemoglobin (Hb) ≥70 g/L;
• •2. White blood cell count (WBC) ≥3.0×109/L; Neutrophil count (NEUT) ≥1.5×109/L;
• •3. Platelet count (PLT) ≥100×109/L;
• •4. Liver function (aspartate aminotransferase AST or alanine aminotransferase ALT) level ≤2.5 times the upper limit of normal value (ULN); Renal function (serum creatinine sCr) level ≤1.5 times the upper limit of the normal value (ULN). Total bilirubin (TBIL) ≤1.5 times the upper limit of the normal value (ULN).
• •8. The expected survival period is more than three months.